Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352111 | 0.95 | TSHR (0.43) | TSHRALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL11030873 | 0.95 | TSHR (0.46) | TSHRALDH1A1CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL9425660 | 0.92 | LMNA (0.46) | TSHRALDH1A1CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL13030024 | 0.90 | LMNA (0.50) | TSHRLMNADNM1FAAHTRPV1 | |
| SCHEMBL5076605 | 0.90 | LMNA (0.50) | TSHRLMNADNM1FAAHTRPV1 | |
| SCHEMBL10629985 | 0.90 | LMNA (0.50) | TSHRLMNADNM1FAAHTRPV1 | |
| SCHEMBL5080046 | 0.90 | LMNA (0.50) | TSHRLMNADNM1FAAHTRPV1 | |
| SCHEMBL22465774 | 0.90 | LMNA (0.50) | TSHRLMNADNM1FAAHTRPV1 | |
| SCHEMBL2103084 | 0.90 | LMNA (0.50) | TSHRLMNADNM1FAAHTRPV1 | |
| SCHEMBL16024020 | 0.90 | LMNA (0.50) | TSHRLMNADNM1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20220402965-A1 | STEROL ANALOGS AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2022-12-22 | — | — | US | disclosed |
| EP-3852764-A1 | STEROL ANALOGS AND USES THEREOF | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020061332-A1 | STEROL ANALOGS AND USES THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2014089239-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2188296-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009029844-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009029844-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | WAPL, WDR1, DUSP1 | TSHR 4260/4885ALDH1A1 1064/4885CYP3A4 2982/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TSHR 2733/4885ALDH1A1 3151/4885CYP3A4 4393/4885 |
| US-20220402965-A1 | STEROL ANALOGS AND USES THEREOF | NPC1L1, NPC1, SREBF2 | TSHR 2985/4885ALDH1A1 2799/4885CYP3A4 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.